Lisa Astor

Articles

Laparoscopic Surgery Found to Be Noninferior to Open Surgery Method for CRC Liver Metastases

June 3rd 2019

Similar long-term rates of survival were seen in patients with colorectal cancer and liver metastases regardless of whether the patient underwent laparoscopic or open liver surgery.

Enzalutamide Increases Survival in mHSPC Over Other Anti-Androgens

June 2nd 2019

Almost 80% of men with metastatic hormone-sensitive prostate cancer treated with enzalutamide plus standard of care (SOC) were alive after 3 years compared with 72% of patients who received a different non-steroidal anti-androgen plus SOC.

Pembrolizumab OS Rates Continue to Impress in NSCLC at 5 Years

June 1st 2019

After 5 years, newly diagnosed patients with advanced non–small cell lung cancer demonstrated an overall survival (OS) rate of 23.2% from treatment with pembrolizumab monotherapy and previously treated patients had an OS rate of 15.5%.

FDA Grants Lasofoxifene Fast Track Designation for ER+/ESR1-Mutant Metastatic Breast Cancer

May 29th 2019

The FDA has granted a fast track designation to lasofoxifene for use as a treatment of female patients with estrogen receptor–positive, HER2-negative metastatic breast cancer who harbor ESR1 mutations.

Pediatric Precision Medicine Approach Proven Possible in Pediatric MATCH Trial

May 16th 2019

About a quarter of pediatric patients with cancer were able to be screened for targetable alterations in their tumor and directed to a treatment targeting that alteration of pathway in the screening protocol of the National Cancer Institute-Children’s Oncology Group Pediatric MATCH trial.

FDA Grants P-BCMA-101 CAR T-Cell Therapy Orphan Drug Designation for Myeloma

May 14th 2019

The FDA has granted an orphan drug designation to the autologous CAR T-cell therapy P-BCMA-101 for the treatment of patients with relapsed/refractory multiple myeloma.

Pembrolizumab Plus Lenvatinib Elicits Responses in Urothelial Cancer

March 11th 2019

Combining lenvatinib and pembrolizumab led to a 25% overall response rate in patients with urothelial carcinoma and was associated with a manageable safety profile.

Using TMB and PD-L1 Together Could Guide Immunotherapy Decisions in NSCLC

January 29th 2019

Until more biomarkers are available, the use of tumor mutational burden with PD-L1 expression could help oncologists further personalize immunotherapy choices for patients with non–small cell lung cancer.

Expert Stresses Significance of Durvalumab Success in Stage III NSCLC

January 28th 2019

Findings from the PACIFIC trial have made a significant impact on the treatment of patients with unresectable stage III non–small cell lung cancer, especially in light of the history of treatment options in this setting.

Brahmer Provides a Glimpse of Future Immunotherapeutics in NSCLC

January 28th 2019

Despite the rapidly expanding therapeutic options available in immunotherapy for patients with non-small cell lung cancer, there are still a number of drawbacks to treatment, explaining why not all patients respond to current treatment options.

Targeted Agents Show Promise Against Emerging Oncogenic Drivers in NSCLC

January 28th 2019

Data on many new treatment options have come forward over the past year highlighting the potential to treat more emerging oncogenic drivers impacting smaller subsets of patients with non–small cell lung cancer.

Treatment Options Expand for ROS1, BRAF, and NTRK Alterations in NSCLC

January 27th 2019

A growing focus on smaller oncogenic drivers in lung cancer has opened up new treatment options and many potential drugs in development for patients with less common alterations.

EGFR-Targeted Activity Helps Differentiation Between TKIs in NSCLC

January 27th 2019

The treatment paradigm for EGFR-mutant non–small cell lung cancer has grown significantly with many EGFR TKIs now available to treat patients with this disease.

BRCA Focus in Ovarian Cancer Turns to Preventive Testing for Inherited Mutations

December 13th 2018

The frequency of hereditary mutations that convey an increased risk of ovarian cancer suggests that many cases of the disease are preventable.

Earlier Adjuvant Chemotherapy Benefits Patients With TNBC

December 6th 2018

Delayed treatment with chemotherapy of more than 30 days after surgery for patients with triple-negative breast cancer is associated with worse survival rates and outcomes than those who receive adjuvant chemotherapy within 30 days of their procedure.

Mok Debates First-Line Versus Second-Line TKI Use in Oncogene-Driven NSCLC

July 29th 2018

The use of frontline versus second-line tyrosine kinase inhibitor use is controversial in many oncogene-driven non-small cell lung cancers.

Checkpoint Inhibition Greatest Success in Recent Years for Locally Advanced NSCLC

July 28th 2018

Checkpoint inhibition following chemoradiation has shown remarkable successes for patients with locally advanced non–small cell lung cancer, after more than 2 decades without major advances.

Shepherd Says Molecular Pathology Has Made EGFR+ NSCLC Example for Field Advancements

July 27th 2018

Molecular pathologists have helped to advance translational research significantly for lung cancer over the past 10 years; nowhere is that more obvious than in EGFR-mutant non-small cell lung cancer.

Adding SIRT Does Not Provide Survival Benefit in Advanced HCC, Except in Select Patients

June 20th 2018

Selective internal radiation therapy in combination with sorafenib (Nexavar) did not provide a significant survival improvement compared with sorafenib alone in patients with advanced hepatocellular carcinoma.

Neoadjuvant Chemoradiotherapy May Improve OS Over Adjuvant Standard-of-Care in Pancreatic Cancer

June 4th 2018

Preoperative treatment with chemotherapy and radiation improved overall survival rates for patients with resectable or borderline resectable pancreatic cancer compared with immediate surgery.